{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T14:29:31Z","timestamp":1782570571730,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s12185-023-03704-w","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T06:01:47Z","timestamp":1706162507000},"page":"416-425","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A systematic review and meta-analysis of recombinant human soluble thrombomodulin for the treatment of DIC associated with hematological malignancies"],"prefix":"10.1007","volume":"119","author":[{"given":"Noriaki","family":"Kawano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Fukatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Yamakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohji","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7858-278X","authenticated-orcid":false,"given":"Takayuki","family":"Ikezoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"issue":"1","key":"3704_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s12185-020-02992-w","volume":"113","author":"T Ikezoe","year":"2021","unstructured":"Ikezoe T. Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies. Int J Hematol. 2021;113(1):34\u201344. https:\/\/doi.org\/10.1007\/s12185-020-02992-w.","journal-title":"Int J Hematol"},{"issue":"1","key":"3704_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.thromres.2009.08.017","volume":"125","author":"H Wada","year":"2010","unstructured":"Wada H, Asakura H, Okamoto K, Iba T, Uchiyama T, Kawasugi K, et al. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res. 2010;125(1):6\u201311.","journal-title":"Thromb Res"},{"issue":"1","key":"3704_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/2052-0492-2-20","volume":"2","author":"H Asakura","year":"2014","unstructured":"Asakura H. Classifying types of disseminated intravascular coagulation: clinical and animal models. J Intensive Care. 2014;2(1):20. https:\/\/doi.org\/10.1186\/2052-0492-2-20.","journal-title":"J Intensive Care"},{"issue":"1","key":"3704_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.thromres.2015.03.029","volume":"136","author":"N Takezako","year":"2015","unstructured":"Takezako N, Sekiguchi N, Nagata A, Homma C, Takezako Y, Noto S, et al. Recombinant human thrombomodulin in the treatment of acute myeloid leukemia patients complicated by disseminated intravascular coagulation: retrospective analysis of outcomes between patients treated with heparin and recombinant human thrombomodulin therapy. Thromb Res. 2015;136(1):20\u20133. https:\/\/doi.org\/10.1016\/j.thromres.2015.03.029.","journal-title":"Thromb Res"},{"issue":"4","key":"3704_CR5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.31662\/jmaj.2020-0013","volume":"3","author":"K Yamakawa","year":"2020","unstructured":"Yamakawa K, Ohbe H, Taniguchi K, Matsui H, Fushimi K, Yasunaga H. Time trends of the outcomes and treatment options for disseminated intravascular coagulation: a nationwide observational study in Japan. JMA J. 2020;3(4):313\u201320. https:\/\/doi.org\/10.31662\/jmaj.2020-0013.","journal-title":"JMA J"},{"issue":"1","key":"3704_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/ams2.836","volume":"10","author":"R Hisamune","year":"2023","unstructured":"Hisamune R, Mochizuki K, Yamakawa K. Real-world evidence on disseminated intravascular coagulation from Japan. Acute Med Surg. 2023;10(1): e836. https:\/\/doi.org\/10.1002\/ams2.836.","journal-title":"Acute Med Surg"},{"key":"3704_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106356","volume":"94","author":"L Naymagon","year":"2020","unstructured":"Naymagon L, Mascarenhas J. Hemorrhage in acute promyelocytic leukemia: can it be predicted and prevented? Leuk Res. 2020;94: 106356. https:\/\/doi.org\/10.1016\/j.leukres.2020.106356.","journal-title":"Leuk Res"},{"issue":"7","key":"3704_CR8","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/leu.2011.78","volume":"25","author":"S Lehmann","year":"2011","unstructured":"Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Mollgard L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25(7):1128\u201334.","journal-title":"Leukemia"},{"issue":"1","key":"3704_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3324\/haematol.2011.046490","volume":"97","author":"JS McClellan","year":"2012","unstructured":"McClellan JS, Kohrt HE, Coutre S, Gotlib JR, Majeti R, Alizadeh AA, et al. Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica. 2012;97(1):133\u20136.","journal-title":"Haematologica"},{"issue":"2","key":"3704_CR10","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.1016\/j.clml.2018.11.004","volume":"19","author":"WFD Silva Jr","year":"2019","unstructured":"Silva WFD Jr, Rosa LID, Marquez GL, Bassolli L, Tucunduva L, Silveira DRA, et al. Real-life outcomes on acute promyelocytic leukemia in Brazil\u2014early deaths are still a problem. Clin Lymphoma Myeloma Leuk. 2019;19(2):e116\u201322.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"3704_CR11","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s12185-019-02740-9","volume":"110","author":"S Osone","year":"2019","unstructured":"Osone S, Fukushima K, Yano M, Kakazu M, Sano H, Kato Y, et al. Supportive care for hemostatic complications associated with pediatric leukemia: a national survey in Japan. Int J Hematol. 2019;110(6):743\u201350. https:\/\/doi.org\/10.1007\/s12185-019-02740-9.","journal-title":"Int J Hematol"},{"issue":"1","key":"3704_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1538-7836.2006.02267.x","volume":"5","author":"H Saito","year":"2007","unstructured":"Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5(1):31\u201341. https:\/\/doi.org\/10.1111\/j.1538-7836.2006.02267.x.","journal-title":"J Thromb Haemost"},{"issue":"11","key":"3704_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384. https:\/\/doi.org\/10.7326\/M14-2385.","journal-title":"Ann Intern Med"},{"issue":"6","key":"3704_CR14","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/bjh.18654","volume":"200","author":"D Minakata","year":"2023","unstructured":"Minakata D, Fujiwara SI, Yokoyama D, Noguchi A, Aoe S, Oyama T, et al. Relapsed and refractory multiple myeloma: a systematic review and network meta-analysis of the efficacy of novel therapies. Br J Haematol. 2023;200(6):694\u2013703.","journal-title":"Br J Haematol"},{"key":"3704_CR15","first-page":"265","volume":"49","author":"N Kobayashi","year":"1983","unstructured":"Kobayashi N, Maekawa T, Takada M, Tanaka H, Gonmori H. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haematol. 1983;49:265\u201375.","journal-title":"Bibl Haematol"},{"issue":"5","key":"3704_CR16","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1055\/s-0037-1616068","volume":"86","author":"FB Taylor Jr","year":"2001","unstructured":"Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for Disseminated intravascular coagulation. Thromb Haemost. 2001;86(5):1327\u201330.","journal-title":"Thromb Haemost"},{"key":"3704_CR17","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1186\/s12913-014-0579-0","volume":"14","author":"AM Methley","year":"2014","unstructured":"Methley AM, Campbell S, Chew-Graham C, McNally R, CheraghiSohi S. PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res. 2014;14:579. https:\/\/doi.org\/10.1186\/s12913-014-0579-0.","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"3704_CR18","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/jth.12841","volume":"13","author":"K Yamakawa","year":"2015","unstructured":"Yamakawa K, Aihara M, Ogura H, Yuhara H, Hamasaki T, Shimazu T. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis. J Thromb Haemost. 2015;13(4):508\u201319. https:\/\/doi.org\/10.1111\/jth.12841. (Erratum in: J Thromb Haemost. 2015;13(7):1358\u20139).","journal-title":"J Thromb Haemost"},{"issue":"1","key":"3704_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1055\/s-0038-1676345","volume":"119","author":"K Yamakawa","year":"2019","unstructured":"Yamakawa K, Murao S, Aihara M. Recombinant human soluble thrombomodulin in sepsis-induced coagulopathy: an updated systematic review and meta-analysis. Thromb Haemost. 2019;119(1):56\u201365. https:\/\/doi.org\/10.1055\/s-0038-1676345.","journal-title":"Thromb Haemost"},{"issue":"3","key":"3704_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transplant"},{"key":"3704_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2307\/2530643","volume":"45","author":"S Greenland","year":"1985","unstructured":"Greenland S, Robin JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics. 1985;45:55\u201368.","journal-title":"Biometrics"},{"key":"3704_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"issue":"11","key":"3704_CR23","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.leukres.2012.08.012","volume":"36","author":"T Ikezoe","year":"2012","unstructured":"Ikezoe T, Takeuchi A, Isaka M, Arakawa Y, Iwabu N, Kin T, et al. Recombinant human soluble thrombomodulin safely and effectively rescues acute promyelocytic leukemia patients from disseminated intravascular coagulation. Leuk Res. 2012;36(11):1398\u2013402. https:\/\/doi.org\/10.1016\/j.leukres.2012.08.012.","journal-title":"Leuk Res"},{"issue":"1","key":"3704_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2169\/internalmedicine.52.7978","volume":"52","author":"N Kawano","year":"2013","unstructured":"Kawano N, Kuriyama T, Yoshida S, Yamashita K, Ochiai H, Nakazaki S, et al. Clinical features and treatment outcomes of six patients with disseminated intravascular coagulation resulting from acute promyelocytic leukemia and treated with recombinant human soluble thrombomodulin at a single institution. Intern Med. 2013;52(1):55\u201362. https:\/\/doi.org\/10.2169\/internalmedicine.52.7978.","journal-title":"Intern Med"},{"issue":"21","key":"3704_CR25","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1182\/blood.V122.21.2373.2373","volume":"122","author":"K Kawasugi","year":"2013","unstructured":"Kawasugi K, Yamamoto T, Shirafuji N, Ikezoe T, Chi S, Ogino Y, et al. Beneficial effect of anticoagulants in the management of patients with acute promyelocytic leukemia (APL): results of a multicenter, retrospective epidemiologic study of the disseminated intravascular coagulation patients in Japan. Blood. 2013;122(21):2373.","journal-title":"Blood"},{"key":"3704_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.thromres.2018.11.014","volume":"173","author":"N Kurita","year":"2019","unstructured":"Kurita N, Sakamoto T, Kato T, Kusakabe M, Yokoyama Y, Nishikii H, et al. The prognosis of disseminated intravascular coagulation associated with hematologic malignancy and its response to recombinant human thrombomodulin. Thromb Res. 2019;173:57\u201364. https:\/\/doi.org\/10.1016\/j.thromres.2018.11.014.","journal-title":"Thromb Res"},{"issue":"2","key":"3704_CR27","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s12185-015-1899-5","volume":"103","author":"T Aota","year":"2016","unstructured":"Aota T, Wada H, Yamashita Y, Matsumoto T, Ohishi K, Suzuki K, et al. The efficacy of the administration of recombinant human soluble thrombomodulin in patients with DIC. Int J Hematol. 2016;103(2):173\u20139. https:\/\/doi.org\/10.1007\/s12185-015-1899-5.","journal-title":"Int J Hematol"},{"issue":"44","key":"3704_CR28","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012981","volume":"97","author":"M Ookura","year":"2018","unstructured":"Ookura M, Hosono N, Tasaki T, Oiwa K, Fujita K, Ito K, et al. Successful treatment of disseminated intravascular coagulation by recombinant human soluble thrombomodulin in patients with acute myeloid leukemia. Medicine (Baltimore). 2018;97(44): e12981. https:\/\/doi.org\/10.1097\/MD.0000000000012981.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"3704_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s13054-016-1415-1","volume":"20","author":"K Yamakawa","year":"2016","unstructured":"Yamakawa K, Umemura Y, Hayakawa M, Kudo D, Sanui M, Takahashi H, Japan Septic Disseminated Intravascular Coagulation (J-Septic DIC) study group, et al. Benefit profile of anticoagulant therapy in sepsis: a nationwide multicentre registry in Japan. Crit Care. 2016;20(1):229. https:\/\/doi.org\/10.1186\/s13054-016-1415-1.","journal-title":"Crit Care"},{"key":"3704_CR30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1055\/s-0037-1612655","volume":"85","author":"LO Mosnier","year":"2001","unstructured":"Mosnier LO, Meijers JC, Bouma BN. Regulation of fbrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost. 2001;85:5\u201311.","journal-title":"Thromb Haemost"},{"issue":"12","key":"3704_CR31","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.2169\/internalmedicine.41.1130","volume":"41","author":"T Kawanami","year":"2002","unstructured":"Kawanami T, Kurita K, Yamakawa M, Omoto E, Kato T. Cerebrovascular disease in acute leukemia: a clinicopathological study of 14 patients. Intern Med. 2002;41(12):1130\u20134. https:\/\/doi.org\/10.2169\/internalmedicine.41.1130.","journal-title":"Intern Med"},{"issue":"5","key":"3704_CR32","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.thromres.2014.02.025","volume":"133","author":"T Matsushita","year":"2014","unstructured":"Matsushita T, Watanabe J, Honda G, Mimuro J, Takahashi H, Tsuji H, et al. Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation: a retrospective analysis of an open-label, multicenter, post-marketing surveillance study cohort. Thromb Res. 2014;133(5):772\u201381. https:\/\/doi.org\/10.1016\/j.thromres.2014.02.025.","journal-title":"Thromb Res"},{"issue":"5","key":"3704_CR33","doi-asserted-by":"publisher","first-page":"346","DOI":"10.11406\/rinketsu.62.346","volume":"62","author":"C Oyama","year":"2021","unstructured":"Oyama C, Arakawa Y, Ikeda Y, Aoki T, Kubota Y, Isobe K, et al. Chronic-phase chronic myeloid leukemia with intracranial hemorrhage complicated with tumor lysis syndrome. Rinsho Ketsueki. 2021;62(5):346\u201351. https:\/\/doi.org\/10.11406\/rinketsu.62.346. (Japanese).","journal-title":"Rinsho Ketsueki"},{"issue":"2","key":"3704_CR34","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s12185-022-03482-x","volume":"117","author":"M Kusuda","year":"2023","unstructured":"Kusuda M, Nakasone H, Nakamura Y, Kawamura M, Takeshita J, Kawamura S, et al. Very early death within 30 days after diagnosis in patients with acute myeloid leukemia. Int J Hematol. 2023;117(2):198\u2013205. https:\/\/doi.org\/10.1007\/s12185-022-03482-x.","journal-title":"Int J Hematol"},{"key":"3704_CR35","unstructured":"Kawano N, Ikezoe T, Wada H, Shimonodan H, Yoshida S, Kuriyama T, et al. The laboratory, clinical features, and treatment outcomes of intracranial hemorrhage with acute leukemia and disseminated intravascular coagulation. The 84th annual meeting of the Japanese Society of Hematology, 14 Oct 2022."},{"issue":"2","key":"3704_CR36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s12185-018-02567-w","volume":"109","author":"D Minakata","year":"2019","unstructured":"Minakata D, Fujiwara SI, Ikeda T, Kawaguchi SI, Toda Y, Ito S, et al. Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies. Int J Hematol. 2019;109(2):141\u20136. https:\/\/doi.org\/10.1007\/s12185-018-02567-w.","journal-title":"Int J Hematol"},{"issue":"4","key":"3704_CR37","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1007\/s10147-018-1261-z","volume":"23","author":"K Ouchi","year":"2018","unstructured":"Ouchi K, Takahashi S, Chikamatsu S, Ito S, Takahashi Y, Kawai S, et al. Retrospective analysis on the clinical outcomes of recombinant human soluble thrombomodulin for disseminated intravascular coagulation syndrome associated with solid tumors. Int J Clin Oncol. 2018;23(4):790\u20138. https:\/\/doi.org\/10.1007\/s10147-018-1261-z.","journal-title":"Int J Clin Oncol"},{"issue":"9","key":"3704_CR38","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/j.ajem.2016.06.001","volume":"34","author":"C Zhang","year":"2016","unstructured":"Zhang C, Wang H, Yang H, Tong Z. Recombinant human soluble thrombomodulin and short-term mortality of infection patients with DIC: a meta-analysis. Am J Emerg Med. 2016;34(9):1876\u201382.","journal-title":"Am J Emerg Med"},{"key":"3704_CR39","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.thromres.2023.05.009","volume":"226","author":"H Kato","year":"2023","unstructured":"Kato H, Hagihara M, Asai N, Umemura T, Hirai J, Mori N, et al. Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravascular coagulation\u2014a meta-analysis. Thromb Res. 2023;226:165\u201372.","journal-title":"Thromb Res"},{"issue":"4","key":"3704_CR40","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.thromres.2014.07.033","volume":"134","author":"H Wada","year":"2014","unstructured":"Wada H, Japanese Society of Thrombosis Hemostasis\/DIC Subcommittee, Okamoto K, Iba T, Kushimoto S, Kawasugi K, Gando S, Madoiwa S, Uchiyama T, Mayumi T, Seki Y. Addition of recommendations for the use of recombinant human thrombomodulin to the \u201cExpert consensus for the treatment of disseminated intravascular coagulation in Japan.\u201d Thromb Res. 2014;134(4):924\u20135. https:\/\/doi.org\/10.1016\/j.thromres.2014.07.033.","journal-title":"Thromb Res"},{"issue":"15","key":"3704_CR41","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","volume":"133","author":"MA Sanz","year":"2019","unstructured":"Sanz MA, Fenaux P, Tallman MS, Estey EH, L\u00f6wenberg B, Naoe T, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133(15):1630\u201343. https:\/\/doi.org\/10.1182\/blood-2019-01-894980.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03704-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-023-03704-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03704-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T13:14:37Z","timestamp":1711199677000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-023-03704-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["3704"],"URL":"https:\/\/doi.org\/10.1007\/s12185-023-03704-w","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]},"assertion":[{"value":"4 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T.I received a research grant from Asahi Kasei Pharma. All other authors have no grant and personal fee regarding the present study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}